Fierce New Product Planning 2024

Forecasting in large organisations faces a number of challenges that go beyond the forecast itself. The bigger the number of stakeholders and assets, the bigger the need for assumption consistency and transparency and alignment on an agreed forecasting process. As much as Excel is capable of supporting very complex forecasting models, additional layers of functionality are required to meet the operational and organisational challenges in this situation. In absence of an obvious gold-standard, which strategies do different types of organisations pursue to make the forecasting process most efficient?
 
It appears that the topics of IRA and the impact of AI rank high in influencing forecasting both near term and long term. How do forecasters deal with the impact and uncertainties around the IRA? Where do experienced forecasters see the most opportunity for AI to either improve forecast accuracy, help with demand planning or support insightful analytics?
 
Join our panel of experienced forecasting professionals to discuss the above questions and hear their vision of the future in forecasting.

Explore the transformative potential of generative AI in enhancing market and competitive intelligence workflows, delivering faster and more accurate insights. This presentation will provide an overview of cutting-edge AI technologies, including Large Language Models (LLMs) and AI Agents, and their practical applications for understanding R&D pipelines and bringing treatments to market.

Key Topics Include:

1. Generative AI and AI Agents: Transforming market analysis and forecasting
2. Advanced AI tools: Smarter data extraction 
3. AlphaSense: The largest source of equity research and clinical trial reports
4. Gen AI: Risks and benefits ahead
   
   AlphaSense, an AI-powered market intelligence platform, enables executives to make confident, data-driven decisions with unparalleled speed. With the industry’s most comprehensive collection of equity research alongside company presentations and clinical trial data, AlphaSense delivers robust solutions for drug pipeline analysis, forecasting, and due diligence.
   
   

Networking Break

This panel will provide a comprehensive examination of the evolving landscape of market access and pricing strategies in the wake of the Inflation Reduction Act (IRA), featuring insights from experts across the pharmaceutical industry.

• Disrupting the Status Quo - Panelists will explore how the IRA fundamentally shifts the balance of power in pharmaceutical pricing and market access, highlighting the strategic challenges and opportunities for companies navigating Medicare Part D changes.
• Strategies for adapting business models under the IRA, focusing on new pricing strategies, transparency, and innovation within fiscal constraints.
• An examination of the IRA's impact on innovation and smaller biotech firms, addressing funding, investment, and regulatory challenges.
• Discussion on international market trends and their influence on drug pricing and access strategies.
• Effective strategies for engaging with payers to enhance drug accessibility and affordability in the context of new global policies and economic pressures.

Asset development is often highly centered around obtaining regulatory approval. This clinically-minded lens puts market adoption at risk. In this session, we’ll discuss how new approaches to asset development which wholistically integrate both clinical and commercial considerations can de-risk development costs, maximize uptake, and help support a better value creation narrative for investors or other key stakeholders. We’ll look at a case study of how an early stage biotech used this approach to successfully prove their asset’s worth, secure capital, and advance development. Join us as we share with you our thoughts on Rethinking Asset Development: The Power of Commercial Insights.

• Explore strategies for enhancing integration and communication between R&D, clinical, and commercial teams.
• Discuss the importance of aligning these teams early in the development process to ensure successful asset progression.
• Share case studies demonstrating successful cross-functional collaboration and its impact on project outcomes.